In the BioHarmony Drug Report Database
Ripretinib
Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and platelet-derived growth factor receptor alpha. Qinlock’s patents are valid until 2040-08-12 (FDA).
Trade Name
|
Qinlock |
|---|---|
Common Name
|
ripretinib |
ChEMBL ID
|
CHEMBL4216467 |
Indication
|
gastrointestinal stromal tumors |
Drug Class
|
Retinol derivatives; tyrosine kinase inhibitors |
Image (chem structure or protein)